GlaxoSmithKline
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CRβ’ and Lisinopril to Its Components
- Conditions
- Hypertension
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT00556920
- Locations
- πΊπΈ
GSK Investigational Site, Buffalo, New York, United States
Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.
- Conditions
- Hypertension
- First Posted Date
- 2007-11-12
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00557128
- Locations
- πΊπΈ
GSK Investigational Site, Austin, Texas, United States
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 60
- Registration Number
- NCT00555061
- Locations
- π¨π³
GSK Investigational Site, Taipei, Taiwan
GSK1349572 First Time in Human Study
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT00555035
- Locations
- πΊπΈ
GSK Investigational Site, Evansville, Indiana, United States
Dose Response and Efficacy of GW842166 in Pain
- Conditions
- Healthy Subjects
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00554762
A Study to Evaluate GSK1325760A - a Long-Term Extension Study
- Conditions
- Pulmonary Arterial HypertensionHypertension, Pulmonary
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2012-11-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00554619
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
Effect of GSK1160724 In Healthy Volunteers
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2017-09-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT00555022
- Locations
- π¬π§
GSK Investigational Site, Harrow, Middlesex, United Kingdom
A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder
- Conditions
- Social Phobia
- Interventions
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 35
- Registration Number
- NCT00555139
- Locations
- πͺπΈ
GSK Investigational Site, Terrassa - Barcelona, Spain
A Study of SB751689 in Japanese Postmenopausal Women
- Conditions
- Osteoporosis
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 18
- Registration Number
- NCT00554255
- Locations
GSK Investigational Site
The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder
- Conditions
- Overactive Bladder
- First Posted Date
- 2007-11-04
- Last Posted Date
- 2010-10-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 55
- Registration Number
- NCT00553657
- Locations
- π¦πΊ
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia